Carisma Therapeutics (NASDAQ:CARM – Get Free Report) and Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.
Analyst Ratings
This is a summary of current ratings and price targets for Carisma Therapeutics and Sagimet Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Carisma Therapeutics | 0 | 5 | 1 | 1 | 2.43 |
| Sagimet Biosciences | 0 | 1 | 4 | 0 | 2.80 |
Carisma Therapeutics currently has a consensus target price of $1.93, suggesting a potential upside of 902.60%. Sagimet Biosciences has a consensus target price of $22.40, suggesting a potential upside of 913.57%. Given Sagimet Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Carisma Therapeutics.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Carisma Therapeutics | $19.63 million | 0.41 | -$86.88 million | ($1.56) | -0.12 |
| Sagimet Biosciences | $2.00 million | 33.90 | -$27.88 million | ($1.43) | -1.55 |
Sagimet Biosciences has lower revenue, but higher earnings than Carisma Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Carisma Therapeutics has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500.
Insider & Institutional Ownership
44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 12.6% of Carisma Therapeutics shares are held by company insiders. Comparatively, 17.6% of Sagimet Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Carisma Therapeutics and Sagimet Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Carisma Therapeutics | -314.78% | -957.20% | -96.39% |
| Sagimet Biosciences | N/A | -23.63% | -22.91% |
Summary
Sagimet Biosciences beats Carisma Therapeutics on 12 of the 15 factors compared between the two stocks.
About Carisma Therapeutics
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
About Sagimet Biosciences
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
